Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSMOTCMKTS:EVTCYNASDAQ:LEGNNASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$104.92+0.3%$106.72$64.11▼$139.13$5.17B0.46687,208 shs485,793 shsEVTCYEvotec$3.78-4.5%$3.77$14.22▼$26.57$1.25B0.982,407 shs168,327 shsLEGNLegend Biotech$28.75-0.8%$31.79$27.34▼$60.87$5.28B0.21.30 million shs2.15 million shsNUVLNuvalent$73.63-1.5%$70.99$55.54▼$113.51$5.37B1.42493,525 shs532,918 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+0.27%-0.14%-6.56%-17.74%+39.50%EVTCYEvotec-4.55%-6.20%-11.48%-10.43%-22.22%LEGNLegend Biotech-0.76%-0.55%-17.74%-17.88%-31.68%NUVLNuvalent-1.51%+0.19%-4.07%-1.80%+11.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXSMAxsome Therapeutics4.8097 of 5 stars4.53.00.04.52.64.20.6EVTCYEvotecN/AN/AN/AN/AN/AN/AN/AN/ALEGNLegend Biotech3.3178 of 5 stars4.52.00.00.03.51.70.6NUVLNuvalent2.4884 of 5 stars3.52.00.00.02.93.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.07Buy$172.1464.07% UpsideEVTCYEvotec 0.00N/AN/AN/ALEGNLegend Biotech 2.91Moderate Buy$76.20165.04% UpsideNUVLNuvalent 2.90Moderate Buy$115.5056.87% UpsideCurrent Analyst Ratings BreakdownLatest EVTCY, LEGN, NUVL, and AXSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.005/14/2025AXSMAxsome TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025LEGNLegend BiotechTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$88.00 ➝ $71.005/14/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$55.00 ➝ $55.005/7/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$200.00 ➝ $180.005/6/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$160.00 ➝ $165.005/6/2025AXSMAxsome TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$160.00 ➝ $162.004/29/2025AXSMAxsome TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$190.00 ➝ $193.004/22/2025LEGNLegend BiotechRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$84.00 ➝ $84.004/16/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.004/8/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$432.16M11.95N/AN/A$1.18 per share88.92EVTCYEvotec$572.16M2.18$0.04 per share105.53$2.52 per share1.50LEGNLegend Biotech$728.30M7.25N/AN/A$6.88 per share4.18NUVLNuvalentN/AN/AN/AN/A$10.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.77N/A37.21N/A-74.47%-223.51%-39.88%8/4/2025 (Estimated)EVTCYEvotec$7.14M$0.419.22∞N/A20.85%16.02%7.81%N/ALEGNLegend Biotech-$518.25M-$0.59N/AN/AN/A-66.92%-29.69%-19.45%8/8/2025 (Estimated)NUVLNuvalent-$126.22M-$4.39N/AN/AN/AN/A-28.63%-27.15%8/14/2025 (Estimated)Latest EVTCY, LEGN, NUVL, and AXSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LEGNLegend Biotech-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A3/11/2025Q4 2024LEGNLegend Biotech-$0.39$0.07+$0.46$0.07$179.00 million$186.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/AEVTCYEvotecN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics3.222.112.04EVTCYEvotec0.532.572.50LEGNLegend Biotech0.274.984.90NUVLNuvalentN/A23.0723.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%EVTCYEvotecN/ALEGNLegend Biotech70.89%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.30%EVTCYEvotecN/ALEGNLegend Biotech0.02%NUVLNuvalent12.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.24 million37.84 millionOptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableLEGNLegend Biotech1,070183.76 million182.60 millionOptionableNUVLNuvalent4071.81 million62.16 millionOptionableEVTCY, LEGN, NUVL, and AXSM HeadlinesRecent News About These CompaniesNuvalent, Inc. Reports Q1 2025 Financial ResultsMay 31 at 12:07 AM | tipranks.comNuvalent (NASDAQ:NUVL) Stock Price Up 6.2% - Time to Buy?May 30 at 2:31 PM | marketbeat.comSquarepoint Ops LLC Reduces Position in Nuvalent, Inc. (NASDAQ:NUVL)May 29 at 4:19 AM | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Shares Sold by Polar Asset Management Partners Inc.May 28 at 5:36 AM | marketbeat.comVoloridge Investment Management LLC Has $13.37 Million Holdings in Nuvalent, Inc. (NASDAQ:NUVL)May 26, 2025 | marketbeat.comTwo Sigma Advisers LP Decreases Stake in Nuvalent, Inc. (NASDAQ:NUVL)May 25, 2025 | marketbeat.comTwo Sigma Investments LP Reduces Stock Position in Nuvalent, Inc. (NASDAQ:NUVL)May 25, 2025 | marketbeat.comNuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal yearMay 24, 2025 | investing.comTwinbeech Capital LP Invests $2.32 Million in Nuvalent, Inc. (NASDAQ:NUVL)May 24, 2025 | marketbeat.comDeutsche Bank AG Has $2.79 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL)May 24, 2025 | marketbeat.comMan Group plc Purchases 41,447 Shares of Nuvalent, Inc. (NASDAQ:NUVL)May 23, 2025 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of "Moderate Buy" from BrokeragesMay 23, 2025 | marketbeat.comWoodline Partners LP Grows Stake in Nuvalent, Inc. (NASDAQ:NUVL)May 22, 2025 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Shares Acquired by Bank of America Corp DEMay 22, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires Shares of 17,366 Nuvalent, Inc. (NASDAQ:NUVL)May 22, 2025 | marketbeat.comVestal Point Capital LP Makes New $46.97 Million Investment in Nuvalent, Inc. (NASDAQ:NUVL)May 21, 2025 | marketbeat.comSoleus Capital Management L.P. Has $8.17 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL)May 21, 2025 | marketbeat.comRafferty Asset Management LLC Increases Stake in Nuvalent, Inc. (NASDAQ:NUVL)May 21, 2025 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of "Moderate Buy" from AnalystsMay 21, 2025 | americanbankingnews.comTema Etfs LLC Acquires New Stake in Nuvalent, Inc. (NASDAQ:NUVL)May 20, 2025 | marketbeat.comSandia Investment Management LP Boosts Holdings in Nuvalent, Inc. (NASDAQ:NUVL)May 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVTCY, LEGN, NUVL, and AXSM Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$104.92 +0.28 (+0.27%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$105.00 +0.08 (+0.08%) As of 05/30/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Evotec OTCMKTS:EVTCY$3.78 -0.18 (-4.55%) As of 05/29/2025Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Legend Biotech NASDAQ:LEGN$28.75 -0.22 (-0.76%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$28.90 +0.15 (+0.50%) As of 05/30/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Nuvalent NASDAQ:NUVL$73.63 -1.13 (-1.51%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$74.58 +0.95 (+1.30%) As of 05/30/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
